Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial

被引：0

作者：

Archana Rai

Kim A. Connelly

Subodh Verma

C. David Mazer

Hwee Teoh

Ming-Yen Ng

Idan Roifman

Adrian Quan

Marina Pourafkari

Laura Jimenez-Juan

Venkat Ramanan

Yin Ge

Djeven P. Deva

Andrew T. Yan

机构：

[1] St Michael’s Hospital,Division of Cardiology, Department of Medical Imaging

[2] University of Toronto,Terrence Donnelly Heart Center

[3] St Michael’s Hospital,Keenan Research Center

[4] Li Ka Shing Knowledge Institute,Division of Cardiac Surgery

[5] St Michael’s Hospital,Department of Anesthesia

[6] St Michael’s Hospital,Division of Endocrinology and Metabolism

[7] St Michael’s Hospital,Department of Diagnostic Radiology

[8] St Michael’s Hospital,Schulich Heart Center

[9] HKU-Shenzhen Hospital and Li Ka Shing Faculty of Medicine,undefined

[10] The University of Hong Kong,undefined

[11] Sunnybrook Health Sciences Center,undefined

[12] Queen’s University,undefined

来源：

Acta Diabetologica | 2022年 / 59卷

关键词：

Empagliflozin; SGLT2 inhibitors; Diabetes; LV diastolic function;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：575 / 578

页数：3

共 31 条

[1] Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
Rai, Archana
Connelly, Kim A.
Verma, Subodh
Mazer, C. David
Teoh, Hwee
Ng, Ming-Yen
Roifman, Idan
Quan, Adrian
Pourafkari, Marina
Jimenez-Juan, Laura
Ramanan, Venkat
Ge, Yin
Deva, Djeven P.
Yan, Andrew T.
ACTA DIABETOLOGICA, 2022, 59 (04) : 575 - 578
[2] Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
Pourafkari, Marina
Connelly, Kim A.
Verma, Subodh
Mazer, C. David
Teoh, Hwee
Quan, Adrian
Goodman, Shaun G.
Rai, Archana
Ng, Ming Yen
Deva, Djeven P.
Triverio, Piero
Jiminez-Juan, Laura
Yan, Andrew T.
Ge, Yin
CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
[3] IGFBP7 and left ventricular mass regression: a sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial
Puar, Pankaj
Mistry, Nikhil
Connelly, Kim A.
Yan, Andrew T.
Quan, Adrian
Teoh, Hwee
Pan, Yi
Verma, Raj
Hess, David A.
Verma, Subodh
Mazer, C. David
ESC HEART FAILURE, 2023, 10 (03): : 2113 - 2119
[4] Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Connelly, Kim A.
Mazer, C. David
Puar, Pankaj
Teoh, Hwee
Wang, Chao-Hung
Mason, Tamique
Akhavein, Farhad
Chang, Ching-Wen
Liu, Min-Hui
Yang, Ning-, I
Chen, Wei-Siang
Juan, Yu-Hsiang
Opingari, Erika
Salyani, Yaseen
Barbour, William
Pasricha, Aryan
Ahmed, Shamon
Kosmopoulos, Andrew
Verma, Raj
Moroney, Michael
Bakbak, Ehab
Krishnaraj, Aishwarya
Bhatt, Deepak L.
Butler, Javed
Kosiborod, Mikhail N.
Lam, Carolyn S. P.
Hess, David A.
Coelho-Filho, Otavio Rizzi
Lafreniere-Roula, Myriam
Thorpe, Kevin E.
Quan, Adrian
Leiter, Lawrence A.
Yan, Andrew T.
Verma, Subodh
CIRCULATION, 2023, 147 (04) : 284 - 295
[5] Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
Nesti, Lorenzo
Pugliese, Nicola Riccardo
Sciuto, Paolo
Trico, Domenico
Dardano, Angela
Baldi, Simona
Pinnola, Silvia
Fabiani, Iacopo
Di Bello, Vitantonio
Natali, Andrea
CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
[6] Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
Lorenzo Nesti
Nicola Riccardo Pugliese
Paolo Sciuto
Domenico Trico
Angela Dardano
Simona Baldi
Silvia Pinnola
Iacopo Fabiani
Vitantonio Di Bello
Andrea Natali
Cardiovascular Diabetology, 21
[7] Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
Natali, Andrea
Nesti, Lorenzo
Fabiani, Iacopo
Calogero, Enrico
Di Bello, Vitantonio
CARDIOVASCULAR DIABETOLOGY, 2017, 16
[8] Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
Andrea Natali
Lorenzo Nesti
Iacopo Fabiani
Enrico Calogero
Vitantonio Di Bello
Cardiovascular Diabetology, 16
[9] The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Sepehr Gohari
Tara Reshadmanesh
Hadi Khodabandehloo
Amir Karbalaee-Hasani
Hassan Ahangar
Shahram Arsang-Jang
Faramarz Ismail-Beigi
Mohsen Dadashi
Samin Ghanbari
Homa Taheri
Mojtaba Fathi
Muhammad Javad Muhammadi
Reyhaneh Mahmoodian
Atieh Asgari
Mohammadreza Tayaranian
Mehdi Moharrami
Mahsa Mahjani
Bijan Ghobadian
Hossein Chiti
Sheida Gohari
Diabetology & Metabolic Syndrome, 14
[10] The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Gohari, Sepehr
Reshadmanesh, Tara
Khodabandehloo, Hadi
Karbalaee-Hasani, Amir
Ahangar, Hassan
Arsang-Jang, Shahram
Ismail-Beigi, Faramarz
Dadashi, Mohsen
Ghanbari, Samin
Taheri, Homa
Fathi, Mojtaba
Muhammadi, Muhammad Javad
Mahmoodian, Reyhaneh
Asgari, Atieh
Tayaranian, Mohammadreza
Moharrami, Mehdi
Mahjani, Mahsa
Ghobadian, Bijan
Chiti, Hossein
Gohari, Sheida
DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):

← 1 2 3 4 →